NASDAQ$IRWD

Ironwood Pharmaceuticals Inc. · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

Ironwood Pharmaceuticals reported a strong finish to 2020, driven by U.S. LINZESS net sales growth and profitability.

Ironwood Pharmaceuticals reported fourth quarter and full year 2020 results, exceeding or meeting full year 2020 financial guidance. The company's performance was driven by U.S. LINZESS net sales growth of 10% year-over-year in 2020. Ironwood delivered its second full year of profits and ended the year with $363 million in cash and cash equivalents.

  • U.S. LINZESS net sales grew 10% year-over-year in 2020.
  • Ironwood delivered its second full year of profits.
  • The company ended 2020 with $363 million in cash and cash equivalents.
  • Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5%.

Headline financials

Total Revenue

$117M

Previous: $126M-7.6%
EPS (adj)

$0.36

Previous: $0.30+20.0%
Capital Expenditures

$28K

Previous: $2.67M-99.0%
Free Cash Flow

$51.5M

Previous: $24.9M+106.7%
Net Income

$106M

Previous: -$1.6M+6725.0%
Operating Income

$51.4M

Previous: $1.18M+4265.7%
Gross Profit

$116M

Previous: $115M+0.4%
Cash & Equivalents

$363M

Previous: $177M+105.1%
Total Assets

$559M

Previous: $403M+38.9%
Stock-Based Comp

$10M

Previous: $5.49M+82.4%

Revenue & EPS history

Ironwood Pharmaceuticals · Revenue · Quarterly

$117M

Q4 2020-7.6%vs Q4 2019
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Ironwood Pharmaceuticals · $71M total across 1 segment · Q1 2020

  • LINZESS Collaboration
    $71M

Forward guidance

Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5%. The company provided full year 2021 total revenue guidance of $370 to $385 million and adjusted EBITDA guidance of >$190 million.

Tailwinds

  • U.S. LINZESS net sales growth of 3 to 5% is expected in 2021
  • Full year 2021 total revenue guidance of $370 to $385 million
  • Adjusted EBITDA guidance of >$190 million for full year 2021

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-1.0%

Avg return

Earnings day

-0.3%

Avg return

5 days after

-1.2%

Avg return

30 days after

44%

28 / 64 earnings

Positive

+32.8%

Q3 2025

Best reaction

-29.5%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-13.9%-15.5%-31.5%
Q4 2025-11.4%-5.8%-19.3%
Q3 2025+32.8%+63.5%+92.2%
Q1 2025-4.4%+0.0%+5.1%
Q4 2024-5.3%-12.9%-17.5%
Q3 2024-1.6%-12.9%-31.9%
Q2 2024-29.5%-25.3%-25.0%
Q1 2024-13.8%-18.3%-21.8%
Q4 2023-5.6%-4.0%-41.6%
Q3 2023+5.5%+5.6%+13.5%
Q2 2023-15.3%-11.3%-24.2%
Q1 2023+1.5%-2.4%+4.9%
Q4 2022+5.8%+3.9%-7.4%
Q3 2022+3.7%+6.8%+11.9%
Q2 2022+5.9%+5.6%-2.9%
Q1 2022-3.0%-8.4%-9.0%
Q4 2021-2.5%-1.2%+13.5%
Q3 2021+0.4%-1.2%-14.6%
Q2 2021+3.2%+4.3%-1.5%
Q1 2021+1.3%+1.5%+9.3%
Q4 2020-7.0%-6.6%+12.3%
Q3 2020+4.0%+12.4%+16.8%
Q2 2020+5.8%+3.0%+1.5%
Q1 2020-3.2%+2.5%-5.3%
Q4 2019-3.2%-2.9%-18.3%
Q3 2019+10.0%+15.9%+27.5%
Q2 2019+2.6%-0.8%-10.0%
Q1 2019-9.9%-12.3%-7.2%
Q4 2018+5.4%+15.1%+3.1%
Q3 2018-15.6%-15.9%-10.3%
Q2 2018-1.1%-1.9%-1.1%
Q1 2018+4.4%+2.6%+2.5%
Q4 2017+6.0%+2.4%+6.0%
Q3 2017+6.8%+1.8%+16.6%
Q2 2017-12.8%-15.5%-9.0%
Q1 2017+5.2%+12.9%+10.5%
Q4 2016-1.6%-4.2%+0.1%
Q3 2016+7.2%+15.2%+22.5%
Q2 2016-6.0%-7.7%-6.9%
Q1 2016+9.3%
Q4 2015+3.4%
Q3 2015-1.2%
Q2 2015+2.4%
Q1 2015-0.1%
Q4 2014-3.1%
Q3 2014-0.9%
Q2 2014-6.2%
Q1 2014+8.4%
Q4 2013+14.1%
Q3 2013-4.0%
Q2 2013+4.2%
Q1 2013-8.9%
Q4 2012-7.7%
Q3 2012+0.0%
Q2 2012-3.8%
Q1 2011-0.5%
Q1 2012-3.5%
Q4 2011-3.4%
Q2 2011-3.4%
Q3 2011-13.6%
Q2 2010+3.3%
Q4 2010+0.1%
Q3 2010+1.4%
Q1 2010-3.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro